231 Views
Tuesday Poster Session
Category: Biliary/Pancreas
Andrew Alabd, MD
Cooper University Hospital
Camden, NJ, United States
Case ID | Pathological diagnosis | Microsatellite instability (MSI) | Immunotherapy drugs used | Target | imRECIST criteria response (% decrease in sum of diameters of target lesion/s) | CA 19-9 prior to therapy (IU/ml) | CA 19-9 at maximal response (IU/ml) |
1 | Ductal adenocarcinoma | Stable | Nivolumab | PD-1 | PR (N/A) | 6400 | 273 |
2 | Ductal adenocarcinoma | High | Pembrolizumab | PD-1 | PR (65%) | 24 | 8 |
3 | Acinar cell cystadenocarcinoma | High | Pembrolizumab | PD-1 | PR (76%) | 3 | 1 |
4 | Intraductal tubular neoplasm with invasive cancer | High | Pembrolizumab | PD-1 | PR (60%) | 127 | 67 |
5 | IPMN with invasive cancer | Stable | Cabiralizumab | CSF-1R | PR (32%) | 17 | 10 |
6 | Mucinous cystic neoplasm with associated invasive cancer | High | Nivolumab | PD-1 | PR (30%) | 105 | 21 |
7 | Ductal adenocarcinoma | Stable | Nivolumab + Cabiralizumab | PD-1 + CSF-1R | PR (42%) | 7 | 7 |
8 | Intraductal tubular neoplasm with invasive cancer | Stable | Pembrolizumab | PD-1 | PR (50%) | 2030 | 43 |
9 | Ductal adenocarcinoma | Stable | Nivolumab + ipilimumab | PD-1 + CTLA4 | PR (N/A) | 776 | 3 |
10 | Ductal adenocarcinoma | Stable | Atezolizumab | PD-1 | PR (31%) | 44 | 29 |